Literature DB >> 32119791

Reply to Sanyal et al.: Overlooked Role of Histopathology in Evaluations for Occupational/Environmental Exposures.

Daniel A Culver1, Sanjay Mukhopadhyay1, Jurgen Behr2,3, Hyun Kim4.   

Abstract

Entities:  

Year:  2020        PMID: 32119791      PMCID: PMC7301741          DOI: 10.1164/rccm.202002-0367LE

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


× No keyword cloud information.
From the Authors: We agree with Dr. Sanyal and colleagues that a careful histologic evaluation of biopsy specimens, when available, is a key aspect of accurately parsing the causes of interstitial fibrosis, and in cases of idiopathic pulmonary fibrosis (IPF) it may also identify environmental exposures that can contribute to progression. Such an evaluation, ideally, would entail close collaboration among pathologists and other members of the interstitial lung disease team to provide context and clinical relevance to the histologic features (1, 2). However, based on the available data, we believe that the authors’ suggestion to perform routine iron staining and polarized light microscopy in cases of typical IPF is excessive. We do agree with the authors that a research effort to characterize dust burden/particulates in the lungs of patients with IPF would be potentially informative and very welcome. It has previously been emphasized that pathologic findings supporting occupational/environmental exposures cannot always distinguish between occupational lung diseases and other forms of pulmonary fibrosis (3). For detection of asbestos bodies, standard evaluation with hematoxylin and eosin appears to be adequate (4, 5), although iron staining can occasionally help reveal asbestos bodies that might have been missed on routine hematoxylin-and-eosin staining. It is well established that the mere finding of asbestos bodies in the lung is insufficient for a pathologic diagnosis of asbestosis. The detection of asbestos bodies only raises more vexing questions for the pathologist, including whether significant interstitial fibrosis is present, whether the fibrosis is present in the appropriate distribution for a diagnosis of asbestosis, whether usual interstitial pneumonia (UIP)-pattern fibrosis should be labeled as asbestosis, and whether UIP in an asbestos-exposed individual represents concurrent IPF or atypical asbestosis. With regard to the last question, some experts in occupational lung disease have suggested that UIP-pattern fibrosis should not be regarded as genuine asbestosis, irrespective of the status of asbestos biomarkers (6). This suggestion—based on an analysis of four asbestos-exposed cohorts in the United Kingdom—challenges the dogma that using iron stains to detect asbestos bodies is a worthwhile exercise in histologic UIP. In contrast to Sanyal and colleagues’s claim that asbestosis is underdiagnosed by pathologists, it suggests that asbestosis may have been historically overdiagnosed by pathologists, especially in patients with histologic evidence of UIP-pattern fibrosis. Routine use of polarized light microscopy for identification of crystalline silica is appealing, but there are no data of which we are aware that demonstrate incremental diagnostic sensitivity for silicosis compared with expected findings on light microscopy (e.g., silicotic nodules, dust macules, and diffuse fibrosis without fibroblast foci). Because background dust accumulation occurs in most normal lungs, the more biologically relevant question is not whether any dust particles (including birefringent silica/silicate particles) are present but whether these particles are significantly in excess of the amount expected in normal lungs, and whether they are associated with a tissue response that would be expected in a true pneumoconiosis (nodules, inflammation, fibrosis, etc.). In this regard, at present, polarized light microscopy should be used at the discretion of the pathologist when histologic features on routine hematoxylin-and-eosin–stained slides suggest the possibility of a pneumoconiosis. Whether finding incidental silica/silicate particles in patients with IPF is of value for diagnosis or clinical care is an open question, especially considering that ongoing dust exposure is already recognized as a contributor to IPF progression. Obtaining a clinical history, as suggested by experts (2), remains the best tool for identifying ongoing significant dust exposure. We doubt that a detailed proscriptive rubric for pathologic reports in interstitial lung disease is necessary or even advisable. Although the histopathologic criteria for calling features of UIP and other key entities in the differential diagnosis (e.g., lymphocytic bronchiolitis in hypersensitivity pneumonitis) are commonly discussed, they have not been precisely defined. Thus, there is poor agreement among lung pathologists for calling these specific histologic patterns (7). In addition, the suggestion that routine templating of reports should include an environmental assessment risks turning the pathology report into a checklist devoid of context and interpretation, which is an unfortunate trend in radiology reports. It is our opinion that descriptive pathology reports are more likely to provide useful information for clinicians. We acknowledge that some cases of pneumoconiosis are missed by pathologists (as well as clinicians and radiologists), but we are not aware of any evidence that mandatory checklists, stains, or polarizing lenses will prevent these mistakes. In summary, we agree with the general suggestion that more careful evaluations of occupational/environmental exposures are needed (8). We think this is best accomplished in the setting of a research effort that includes the appropriate control groups rather than by adhering to a proscriptive standard that may be time consuming, unwieldy, and unevenly interpreted, and may also lead to false reassurance or even misclassification by clinicians.
  8 in total

1.  Usual interstitial pneumonia in asbestos-exposed cohorts - concurrent idiopathic pulmonary fibrosis or atypical asbestosis?

Authors:  Richard L Attanoos; Fouad S Alchami; Frederick D Pooley; Allen R Gibbs
Journal:  Histopathology       Date:  2016-04-20       Impact factor: 5.087

Review 2.  Proposed criteria for mixed-dust pneumoconiosis: definition, descriptions, and guidelines for pathologic diagnosis and clinical correlation.

Authors:  Koichi Honma; Jerrold L Abraham; Keizo Chiyotani; Paul De Vuyst; Pascal Dumortier; Allen R Gibbs; Francis H Y Green; Yutaka Hosoda; Kazuro Iwai; William Jones Williams; Norihiko Kohyama; Gaston Ostiguy; Victor L Roggli; Hisao Shida; Osamu Taguchi; Val Vallyathan
Journal:  Hum Pathol       Date:  2004-12       Impact factor: 3.466

3.  Multidisciplinary interobserver agreement in the diagnosis of idiopathic pulmonary fibrosis.

Authors:  M Thomeer; M Demedts; J Behr; R Buhl; U Costabel; C D R Flower; J Verschakelen; F Laurent; A G Nicholson; E K Verbeken; F Capron; M Sardina; G Corvasce; I Lankhorst
Journal:  Eur Respir J       Date:  2007-12-05       Impact factor: 16.671

4.  Pathologic Separation of Chronic Hypersensitivity Pneumonitis From Fibrotic Connective Tissue Disease-associated Interstitial Lung Disease.

Authors:  Andrew Churg; Joanne L Wright; Christopher J Ryerson
Journal:  Am J Surg Pathol       Date:  2017-10       Impact factor: 6.394

5.  Idiopathic pulmonary fibrosis in asbestos-exposed workers.

Authors:  E A Gaensler; P J Jederlinic; A Churg
Journal:  Am Rev Respir Dis       Date:  1991-09

6.  Asbestos bodies and the diagnosis of asbestosis in chrysotile workers.

Authors:  J Holden; A Churg
Journal:  Environ Res       Date:  1986-02       Impact factor: 6.498

Review 7.  Patient Registries in Idiopathic Pulmonary Fibrosis.

Authors:  Daniel A Culver; Jürgen Behr; John A Belperio; Tamera J Corte; Joao A de Andrade; Kevin R Flaherty; Mridu Gulati; Tristan J Huie; Lisa H Lancaster; Jesse Roman; Christopher J Ryerson; Hyun J Kim
Journal:  Am J Respir Crit Care Med       Date:  2019-07-15       Impact factor: 21.405

8.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.